PROCEPT BioRobotics Corp.: Emporkömmling beseitigt Prostatakrebs mit Spezialroboter
Die meisten Analysten empfehlen BioRobotics entweder zum starken Kauf oder zum Kauf.
53,04 $
1,90%
Echtzeit-Preisindikation
Bid: 52,74 $
Ask: 53,03 $
Was macht PROCEPT BioRobotics Corp?
UnternehmensprofilPROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.
Chart der PROCEPT BioRobotics Corp Aktie
Aktuelle Nachrichten zu PROCEPT BioRobotics Corp
Unsere neuesten Artikel zu PROCEPT BioRobotics Corp
Über "aktien"
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.